EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular and Clinical Characterization of a Founder Mutation Causing G6PC3 Deficiency

Xin Zhen, Michael J Betti, Meltem Ece Kars, Andrew R Patterson, Edgar Alejandro Medina-Torres, Selma Cecilia Scheffler Mendoza, Diana Andrea Herrera Sánchez, Gabriela Lopez-Herrera, Yevgeniya Svyryd, Osvaldo M Mutchinick, Eric R Gamazon, Jeffrey C Rathmell und 5 weitere

Journal of Clinical Immunology · 2025

DOI: 10.1007/s10875-024-01836-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Xin Zhen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Glucose-6-Phosphatase, Founder Effect, Neutropenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

G6PC3 deficiency is a monogenic immunometabolic disorder that causes severe congenital neutropenia type 4. Patients display heterogeneous extra-hematological manifestations, contributing to delayed diagnosis. Here, we investigated the origin and functional consequence of the G6PC3 c.210delC variant found in patients of Mexican descent. Based on the shared haplotypes amongst mutation carriers, we estimated that this variant originated from a founder effect in a common ancestor. Furthermore, by ancestry analysis, we concluded that it appeared in the indigenous Mexican population. At the protein level, we showed that this frameshift mutation leads to an aberrant protein expression in overexpression and patient-derived Epstein-Barr Virus-immortalized B (EBV-B) cells. The neutropenia observed in G6PC3-deficient patients is driven by the intracellular accumulation of the metabolite 1,5-anhydroglucitol-6-phosphate (1,5-AG6P) that inhibits glycolysis. We characterized how the c.210delC variant impacts glycolysis by performing extracellular flux assays on patient-derived EBV-B cells. When treated with 1,5-anhydroglucitol (1,5-AG), the precursor to 1,5-AG6P, patient cells exhibited markedly reduced engagement of glycolysis. Finally, we compared the clinical presentation of patients with the mutation c.210delC and all other G6PC3-deficient patients reported in the literature, and we found that the c.210delC carriers display all prominent clinical features observed in prior patients. In conclusion, G6PC3 c.210delC is a loss-of-function mutation that arose from a founder effect in the indigenous Mexican population. These findings may facilitate the diagnosis of additional patients in this geographical area. Moreover, the in vitro 1,5-AG-dependent functional assay used in our study could be employed to assess the pathogenicity of additional G6PC3 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucose-6-PhosphataseFounder EffectNeutropeniaHumansFemaleMaleCongenital Bone Marrow Failure SyndromesMexicoMutationGlycolysisChildFrameshift MutationB-LymphocytesHerpesvirus 4, HumanChild, Preschool

Stichwörter der Autor:innen

Founder effectG6PC3 deficiencyInborn errors of immunityMetabolic dysfunctionPrimary immunodeficiencySevere congenital neutropenia

Substanzen

Glucose-6-PhosphataseG6PC3 protein, human

Autor:innen und Institutionen

  • Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Division of Molecular Pathogenesis, Department of Pathology Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
  • The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Vanderbilt Center for Immunobiology, Nashville, TN, USA.
  • Immune deficiencies laboratory, National Institute of Pediatrics, Health Secretariat, Mexico City, Mexico.

Förderung

  • NIDDK NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Zhen, X., Betti, M. J., Kars, M. E., Patterson, A. R., Medina-Torres, E. A., Scheffler Mendoza, S. C., Herrera Sánchez, D. A., Lopez-Herrera, G., Svyryd, Y., Mutchinick, O. M., Gamazon, E. R., Rathmell, J. C., Itan, Y., Markle, J., O'Farrill Romanillos, P., Lugo-Reyes, S. O., & Martinez-Barricarte, R. (2025). Molecular and Clinical Characterization of a Founder Mutation Causing G6PC3 Deficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01836-0

Vancouver

Zhen X, Betti MJ, Kars ME, Patterson AR, Medina-Torres EA, Scheffler Mendoza SC, et al. Molecular and Clinical Characterization of a Founder Mutation Causing G6PC3 Deficiency. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-024-01836-0

BibTeX
@article{Zhen2025,
  author = {Zhen, Xin and Betti, Michael J and Kars, Meltem Ece and Patterson, Andrew R and Medina-Torres, Edgar Alejandro and Scheffler Mendoza, Selma Cecilia and Herrera Sánchez, Diana Andrea and Lopez-Herrera, Gabriela and Svyryd, Yevgeniya and Mutchinick, Osvaldo M and Gamazon, Eric R and Rathmell, Jeffrey C and Itan, Yuval and Markle, Janet and O'Farrill Romanillos, Patricia and Lugo-Reyes, Saul Oswaldo and Martinez-Barricarte, Ruben},
  title = {Molecular and Clinical Characterization of a Founder Mutation Causing G6PC3 Deficiency},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  doi = {10.1007/s10875-024-01836-0}
}
Kostenlos starten →